NEW YORK (TheStreet) -- CHANGE IN RATINGS
upgraded at Goldman from Sell to Neutral. Company has better earnings power, given a favorable rate case.
upgraded at Stifel from Hold to Buy. $68 price target. Square footage growth is re-accelerating.
rated new Hold at Dahlman Rose. Company faces significant challenges with the ROH acquisition.
downgraded at Goldman from Buy to Neutral. Company had unfavorable rate cases in Arkansas and Texas.
upgraded at Credit Suisse to Neutral from Underperform as working capital is stabilizing. Price target jumped to $32 from $26.
downgraded at Deutsche from Buy to Hold. Valuation call.
downgraded at Stifel from Buy to Hold. Company still faces risks with its court case in Florida.
downgraded at Citigroup from Buy to Hold. $54 price target. Stock has outperformed its peers since March.
downgraded at Goldman from Neutral to Sell. Valuation call.
upgraded at Goldman from Neutral to Buy. Valuation call, as the company's rate case should be resolve in the next 6-9 months.
rated new Hold at Deutsche Bank. $26 price target. Stock will remain volatile, along with the performance of the overall market.
downgraded at Deutsche from Buy to Hold. Stock is already pricing in a recovery in truckload rates.
downgraded at Stifel from Buy to Hold. Company will struggle through recent managerial changes.
rated new Buy at UBS. $20 price target. Company is a pure play on Bakken, and is oil-heavy.
STOCK COMMENTS / EPS CHANGES
estimates target raised at Citigroup. Shares of ACL now seen reaching $181. Estimates also increased, given strong sales momentum across the board. Buy rating.
estimates increased at UBS through 2011. Company has strong earnings momentum. Neutral rating and $30 price target.
estimates, target boosted at Brean Murray through 2011. Company had a strong quarter, driven by higher renewal rates. Buy rating.
target, estimates raised at BofA/Merrill to $57 from $53. 2010 EPS estimate boosted to $3.15 from $2.95 on strong 2Q results. Reiterate Buy rating.
price target raised at BofA/Merrill to $145 from $138 on new assets acquired from BP. Reiterate Buy rating.
price target higher at BofA/Merrill. APC price target increased a dollar to $76 on confirmed discoveries in Ghana. Reiterate Buy rating.
price target boosted at BofA/Merrill. AZO price target jumped to $225 from $208 on continued industry strength. Reiterate Buy rating.
numbers lowered at Citigroup through 2011. Company saw a weak flu season and will also be hurt by currency changes. Buy rating and new $76 price target.
price target trimmed at Barclays. CRNT price target cut to $11 from $13. Sales trajectory depends on Indian government. Maintain Equal Weight rating.
Enterprise Products Partners
target increased at Barclays to $41 from $39. Shale plays support growth visibility. Reiterate Overweight rating.
estimates increased at Morgan Stanley through 2012. Company is seeing better volume and yields in ground shipping. Equal-weight rating.
price target higher at Barclays. FLR price target increased to $61 from $58 on bookings momentum. Maintain Overweight rating.
estimates, target boosted at UBS. Shares of FLR now seen reaching $61. Estimates also upped, given the company's better backlog. Buy rating.
price target higher at Credit Suisse to $69 from $65. Gulf of Mexico disruption offset by stronger Fluid Control revenues. Maintain Neutral rating.
estimate lifted at Barclays. HON 2010 EPS estimate raised 5 cents to $2.50, 2011 held at $3.15. Positive long cycle orders mark the quarter. Maintain $55 price target.
estimates, target reduced at Citigroup. Shares of ISIL now seen reaching $9, according to Citigroup. Estimates also cut, following the Techwell acquisition. Sell rating.
estimates lowered at Morgan Stanley through 2012. Cereal recall will hurt profits. Overweight rating and $60 price target.
estimates raised at UBS through 2011. Expect further price increases in the tobacco industry. Buy rating and $100 price target.
estimates lowered at UBS through 2011. Company is realizing higher profitability. Sell rating and $8 price target.
price target lowered at Credit Suisse to $35 from $38. Rate base reductions support circulation thesis. Maintain Neutral rating.
estimates, target cut at Citigroup. Shares of MFE now seen reaching $34. Estimates also lowered, given the company's currency risk. Hold rating.
Owens & Minor
numbers reduced at UBS. Shares of OMI now seen reaching $29. Estimates also cut, given lower hospital volumes. Neutral rating.
target upped at UBS. PCL target was boosted to $39. Company is seeing better operating momentum. Neutral rating.
estimates upped at Morgan Stanley through 2012. Company is seeing better results in the Energy and Scientific divisions. Equal-weight rating and $67 price target.
estimates lowered at UBS through 2011. Company is spending more on exploration. Neutral rating and $52 price target.
price target cut at Credit Suisse to $15 from $22. Weak 2Q10 results reveal declining operating leverage. Maintain Neutral rating.
estimates cut at Morgan Stanley through 2011. Company is focusing on growth, rather than profitability. Equal-weight rating.
estimate boosted at BofA/Merrill. UTX 2010 EPS estimate jumped to $4.85 from $4.79 on improved operating leverage and performance. Reiterate Buy rating.
target, estimates raised at BofA/Merrill. VECO price target increased a dollar to $65. 2011 EPS estimate increased to $5.15 on continued strength in the LED cycle. Reiterate Buy rating.
numbers raised at UBS. Shares of VECO now seen reaching $60. Estimates also increased, given the company's new guidance. Buy rating.
This article was written by a staff member of TheStreet.